Sun, Dec 28, 2014, 1:24 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

RADIENT PHARM CP Message Board

  • elijahrev737 elijahrev737 Sep 25, 2013 4:13 PM Flag

    RADIENT FILINGS

     

    -K/A 1 f8k061113a1_radient.htm CURRENT REPORT

    --------------------------------------------------------------------------------

    --------------------------------------------------------------------------------

    CURRENT REPORT FOR ISSUERS SUBJECT TO THE
    1934 ACT REPORTING REQUIREMENTS

    FORM 8-K/A

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act

    Date of Report (Date of Earliest Event Reported): June 18, 2013 (June 11, 2013)

    Radient Pharmaceuticals Corporation

    --------------------------------------------------------------------------------

    (Exact name of registrant as specified in its charter)

    Delaware 001-16695 33-0413161
    (State or other Jurisdiction of
    Incorporation) (Commission File Number) (IRS Employer Identification No.)


    2492 Walnut Avenue, Suite 100, Tustin, California, 92780-7039

    --------------------------------------------------------------------------------

    (Address of principal executive offices (zip code))

    714-505-4461

    --------------------------------------------------------------------------------

    (Registrant’s telephone number, including area code)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a - 12)


    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13d-4(c))




    --------------------------------------------------------------------------------



    Section 1 - Registrant’s Business and Operations

    Item 1.01 - Entry into Material Definitive Agreements

    We filed a Current Report on Form 8-K on June 11, 2013 to disclose our entry into a 5-year license agreement between AMDL Diagnostics, Inc. (“ADI”), a division within our company, and Uni Pharma Co., Ltd. a Taipei Taiwan limited liability company (“UNI”) that provides UNI with a 5-year exclusive license (subject to automatic renewal for an additional 5 years) to RXPC’s Onko-Sure® (formerly called DR-70 cancer blood test kits (the “Tests”), procedures, analyses, data, know how, manufacturing, manufacturing processes, components, trademarks and intellectual property.

    The initial 8-K and the agreement attached as Exhibit 10.1 to the initial 8-K inaccurately disclosed that UNI only has exclusive license rights in Taiwan; however, the final agreement provides UNI with exclusive rights to the license in all of the following territories: Taiwan ROC, China PRC, Hong Kong, Malaysia, Singapore, Indonesia, Thailand, Japan, India, Turkey Australia and New Zealand. We are filing this amendment to disclose same and to file the final version of the agreement as an exhibit.

    Item 9.01 Financial Statements and Exhibits

    This topic is deleted.
 
RXPC
0.00010.0000(0.00%)Jul 2 11:41 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
TherapeuticsMD, Inc.
AMEXFri, Dec 26, 2014 4:01 PM EST
PG&E Corporation
NYSEFri, Dec 26, 2014 4:02 PM EST